SCHEMBL894667

SCHEMBL894667

NC(=O)c1cc(F)c(Cl)nc1Nc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.47
MAPK10 P53779 1/20 0.47
TYK2 P29597 2/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
AURKA O14965 2/20 0.42
RPS6KB1 P23443 1/20 0.42
DHODH Q02127 1/20 0.42
LMNA P02545 1/20 0.41
CSF1R P07333 2/20 0.40
JAK2 O60674 3/20 0.40
JAK1 P23458 3/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
BTK Q06187 1/20 0.39
SYK P43405 3/20 0.39
ZAP70 P43403 1/20 0.39
JAK3 P52333 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL894633 0.87 KEAP1 (0.55) KEAP1NFE2L2AURKADHODHCSNK2A2
SCHEMBL10169403 0.83 SYK (0.44) MAPK9MAPK10TYK2DHODHLMNA
SCHEMBL894840 0.82 STAT6 (0.55) MAPK9MAPK10TYK2JAK2JAK1
SCHEMBL894971 0.80 SYK (0.52) CSF1RBTKSYKFLT3
SCHEMBL24279936 0.79 KEAP1 (0.55) KEAP1NFE2L2AURKADHODHLMNA
SCHEMBL893639 0.78 JAK3 (0.39) JAK2JAK1BTKJAK3
SCHEMBL893637 0.76 BTK (0.48) JAK2JAK1BTKSYKJAK3
SCHEMBL30474526 0.73 KEAP1 (0.69) MAPK9KEAP1NFE2L2LMNAJAK2
SCHEMBL166218 0.73 KEAP1 (0.69) MAPK9KEAP1NFE2L2LMNAJAK2
SCHEMBL16165503 0.73 SYK (0.61) SYKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440204-B1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-12-18 EP disclosed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
EP-2440204-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS Bristol-Myers Squibb Company (US) 2012-04-18 EP disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO disclosed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT MAPK9 129/4885MAPK10 168/4885TYK2 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.